Highlights in colorectal cancer at ASCO and ESMO GI 2024 by Video Journal of Oncology
David Tougeron, Professor at University of Poitiers Hospital, shared a post by Video Journal of Oncology, on LinkedIn, adding:
“A great overview of ESMO GI 2024 best of including the POCHI trial coordinated by the FFCD.”
Quoting Video Journal of Oncology’s post:
”Check out our NEW podcast episode: Highlights in colorectal cancer at ASCO and ESMO GI 2024.
In this week’s podcast, we will discuss the most recent developments in colorectal cancer from the 2024 ASCO and ESMO Gastrointestinal (GI) Annual Meetings held in Chicago, IL and Munich, Germany respectively.
Join us as five renowned experts discuss highly anticipated findings from clinical trials across different colorectal cancer subtypes:
Heinz Josef Lenz from the University of Southern California first comments on the expanded efficacy analysis from the Phase III CheckMate 8HW study in MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi from the Veneto Institute of Oncology in Padua, Italy, discusses the health-related quality of life outcomes from the trial.
John Strickler from Duke University then provides 32 month follow-up data from the MOUNTAINEER trial of tucatinib and trastuzumab in HER2 positive colorectal cancer.
Major Lee, The University of Pennsylvania, and David TOUGERON, University of Poitiers Hospital, cover practice changing trials in colorectal cancer.
Give it a listen.
Use the time codes to skip to your favourite part of each episode.
SUBSCRIBE so you don’t miss any future episodes.”
Source: David Tougeron/LinkedIn and Video Journal of Oncology/LinkedIn